0 Kommentare
0 Geteilt
683 Ansichten
0 Bewertungen
Suche
Entdecken Sie neue Leute, knüpfen Sie neue Kontakte und schließen Sie neue Freundschaften
-
Newsfeed
- ERKUNDEN
-
Seiten
-
Gruppen
-
Veranstaltungen
-
Reels
-
Blogs
-
Marktplatz
-
Angebote
-
Jobs
-
Bitte loggen Sie sich ein, um liken, teilen und zu kommentieren!
-
ICH Q12 and Pharmaceutical Lifecycle Management: What Companies Need to Know About Post-Approval ChangesNearly seven years after its finalization by the ICH Assembly in November 2019, ICH Q12 (Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management) has officially moved from a forward-looking conceptual framework to an operational regulatory expectation. With the FDA advancing its implementation, the EU clearing legal pathways through Regulation (EU) 2024/1701, and...0 Kommentare 0 Geteilt 663 Ansichten 0 Bewertungen
-
Key Highlights of the NDCT Amendment Rules 2026: Transforming India’s Clinical Research LandscapeThe clinical research and pharmaceutical sectors in India are undergoing a profound evolution. To streamline drug development, eliminate procedural bottlenecks, and align national standards with global frameworks, the Ministry of Health and Family Welfare (MoHFW) and the Central Drugs Standard Control Organization (CDSCO) introduced the landmark New Drugs and Clinical Trials (NDCT) Amendment...0 Kommentare 0 Geteilt 817 Ansichten 0 Bewertungen
-
Mastering PK-Stat Reviews in Bioequivalence Studies: Bridging Data and Regulatory SuccessIn the rigorous world of pharmaceutical development, proving that a generic or alternative formulation matches a brand-name reference product requires far more than just laboratory similarity. It demands undeniable mathematical and statistical proof. At the heart of this process lies the Pharmacokinetic-Statistical (PK-Stat) Review—the critical link that translates raw plasma...0 Kommentare 0 Geteilt 635 Ansichten 0 Bewertungen
-
Mastering Sponsor Oversight in Clinical Trials: Ensuring Quality and ComplianceIn modern clinical research, outsourcing operational tasks to Contract Research Organizations (CROs), vendors, and central laboratories is standard practice. However, there is one critical responsibility that a pharmaceutical or biotech sponsor can never outsource: sponsor oversight. Regulatory authorities worldwide—including the US FDA, EMA, and CDSCO—make it explicitly clear that...0 Kommentare 0 Geteilt 605 Ansichten 0 Bewertungen